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Abstract 
Background: Effective control of the use of anabolic-androgenic steroids (AASs) in 
animal sports is essential in order to ensure both animal welfare and integrity. In 
order to better police their use in Australian and New Zealand greyhound racing, 
thorough metabolic studies have been carried out on a range of registered human 
and veterinary AASs available in the region. 
Results: Canine metabolic data are presented for the AASs boldenone, danazol, 
ethylestrenol, mesterolone, methandriol, nandrolone and norethandrolone. The 
principal phase I metabolic processes observed were the reduction of A-ring 
unsaturations and/or 3-ketones with either 3α,5β- or 3β,5α-stereochemistry, the 
oxidation of secondary 17β-hydroxyl groups and 16α-hydroxylation. The phase II β-
glucuronylation of sterol metabolites was extensive. 
Conclusion: The presented data have enabled the effective analysis of AASs and 
their metabolites in competition greyhound urine samples. 
Key Terms 
1. Greyhound racing. A major industry in Australia and New Zealand, greyhound 
racing in these countries boasts over 30,000 registered participants and attracts over 
AUD2 billion in wagering annually. 
2. Anabolic-androgenic steroids. Despite their infamous reputation as athletic 
performance enhancers, these substances are also considered to have legitimate 
therapeutic applications and many racing jurisdictions have adopted policies of 
control rather than outright bans on their use. 
3. Estrus control. Pharmaceutical suppression of the estrus cycle of the racing 
greyhound bitch is commonplace for husbandry reasons and to maximize the 
animal's racing career. Low dose AAS administration is the generally preferred 
mechanism. 
4. Racing laboratory. A facility specializing in the chemical analysis of biological 
samples taken from racing animals for the purpose of doping control. Modern racing 
laboratories have a heavy reliance on mass spectrometry, commonly supplemented 
with immunoassay techniques for selected targets. 
1 Introduction 
The therapeutic use of anabolic-androgenic steroids (AASs) in racing animals is a 
well established practice. In horse racing, AASs are widely used for the maintenance 
of condition and appetite and to aid recovery from injury or post-surgical 
convalescence. In greyhound racing, AASs are the preferred agents for estrus 
control in bitches, providing strong estrus suppression with few negative side effects 
when compared to progestins or other available estrus suppressants. In addition to 
these relatively benign applications, AASs have the potential to alter the physique or 
psychological nature of a racing animal resulting in enhanced race performance. For 
this reason, their use in most racing jurisdictions is subject to some form of 
regulation. 
In formulating rules and policies relating to AASs the racing regulator must seek a 
balance between animal welfare, racing integrity and public perception. The 
approach adopted by the greyhound racing authorities in Australia and New Zealand 
has been a total ban on the presence of AASs or their metabolites in animals 
presented to race with the exception of ethylestrenol, which is permitted in bitches 
when administered under veterinary supervision for the sole purpose of estrus 
control. This exemption recognizes the significant complications that may arise from 
the use of alternative estrus suppressants and the undesirability of standing a bitch 
down from racing whilst in heat. This policy was implemented across Australia 
between July and October 2008 and in New Zealand in January 2010. 
The new regulations posed a significant challenge for the Australasian racing 
laboratories. AASs typically undergo extensive phase I and II metabolism in vivo and 
a thorough knowledge of the relevant metabolic pathways is essential for effective 
doping control. However, despite a wealth of publications describing human [1,2 and 
references cited therein] and equine [3 and references cited therein] AAS 
metabolism, there is very little published canine data [4-9]. To help rectify this 
situation, the industry initiated a program of scientific research aimed at providing the 
information and resources required for effective testing. The program involved a 
series of controlled canine AAS administration trials followed by extensive chemical 
analysis to elucidate the major metabolic pathways and identify suitable analytical 
targets for doping control. Furthermore, where strategic targets were found to be 
commercially unavailable, efforts were made to synthesize authentic samples for use 
as reference standards. Priority was given to AASs which were locally available 
either as human or veterinary preparations. Thus, investigations have been carried 
out for boldenone undecylenate, danazol, ethylestrenol, mesterolone, methandriol 
dipropionate, nandrolone laurate, norethandrolone and stanozolol. During each 
investigation, useful forensic markers were unambiguously identified and, where 
otherwise unavailable, synthesized and characterized. Stanozolol is the subject of a 
separate publication [10]. The remaining data is presented herein. 
 
2 Experimental 
2.1 Purchased Steroids 
19-Norepiandrosterone (3β-hydroxy-5α-estran-17-one) was purchased from Alltech 
(NSW, Australia). 17-Epiboldenone (17α-hydroxyandrosta-1,4-dien-3-one), 17-
epinandrolone (17α-hydroxyestr-4-en-3-one), ethylestrenol (19-nor-17α-pregn-4-en-
17β-ol), 17β-hydroxy-5β-androst-1-en-3-one, 3α-hydroxy-1α-methyl-5α-androstan-
17-one, 1α-methyl-5α-androstane-3α,17β-diol, 17α-methyl-5β-androstane-3α,17β-
diol and 19-noretiocholanolone (3α-hydroxy-5β-estran-17-one) were purchased from 
the National Measurement Institute (NSW, Australia). Androsta-1,4-diene-3,17-dione, 
androsterone (3α-hydroxy-5α-androstan-17-one), boldenone (17β-hydroxyandrosta-
1,4-dien-3-one), danazol (isoxazolo[4’,3’:2,3]-17α-pregn-4-en-20-yn-17β-ol), 
epiandrosterone (3β-hydroxy-5α-androstan-17-one), estr-4-ene-3,17-dione, 
ethisterone (17β-hydroxy-17α-pregn-4-en-20-yn-3-one), etiocholanolone (3α-
hydroxy-5β-androstan-17-one), methandriol (17α-methylandrost-5-ene-3β,17β-diol), 
17α-methyltestosterone (17β-hydroxy-17α-methylandrost-4-en-3-one), nandrolone 
(17β-hydroxyestr-4-en-3-one) and norethandrolone (17β-hydroxy-19-nor-17α-pregn-
4-en-3-one) were purchased from Sigma (NSW, Australia). 5α-Androst-1-ene-3,17-
dione, 3-epietiocholanolone (3β-hydroxy-5β-androstan-17-one), 5α-estrane-3α,17α-
diol, 5α-estrane-3α,17β-diol, 5α-estrane-3β,17α-diol, 5α-estrane-3β,17β-diol, 5β-
estrane-3α,17α-diol, 5β-estrane-3α,17β-diol, 5β-estrane-3β,17β-diol, 17β-hydroxy-
5α-androst-1-en-3-one, mesterolone (17β-hydroxy-1α-methyl-5α-androstan-3-one), 
17α-methyl-5α-androstane-3α,17β-diol and 17α-methyl-5α-androstane-3β,17β-diol 
were purchased from Steraloids (RI, USA). 
 2.2 Synthesized Steroids 
2.2.1 5β-Androst-1-ene-3,17-dione 
The title compound was formed by oxidation of the corresponding 17β-alcohol. 
Pyridinium chlorochromate (5 mg) was added to a solution of 17β-hydroxy-5β-
androst-1-en-3-one (1 mg) in dichloromethane (4 mL) and mixed by rotation for 4 h 
at room temperature. Excess oxidizing agent was destroyed by the addition of 
sodium bisulfite solution (0.1 M, 4 mL) and the organic phase was dried over 
anhydrous sodium sulfate and dried by evaporation at 60 °C under nitrogen. 
 
2.2.2 5α-Androst-1-ene-3α,17β-diol and 5α-androst-1-ene-3β,17β-diol 
The title 3-epimeric diols were prepared by a simple reduction of the corresponding 
3-ketone. The lithium aluminum hydride reduction of the Δ1-5α-androstan-3-one A-
ring has been described by Bergmann et al. [11] and strongly favours the formation 
of the 3β-alcohol. 
Lithium aluminum hydride (5 mg) was added to a solution of 17β-hydroxy-5α-
androst-1-en-3-one (1 mg) in diethyl ether (4 mL) and mixed by rotation for 1 h at 
room temperature. Excess reducing agent was destroyed by the dropwise addition of 
2-propanol followed by sulfuric acid (1 M, 4 mL) and the organic phase was dried by 
evaporation at 60 °C under nitrogen. GC-MS analysis revealed the existence of two 
peaks in 10.1:1 ratio which were assigned as the 3β- and 3α-alcohols respectively in 
accordance with literature precedent [11]. 
 
2.2.3 5β-Androst-1-ene-3α,17β-diol and 5β-androst-1-ene-3β,17β-diol 
The title 3-epimeric diols were prepared from 17β-hydroxy-5β-androst-1-en-3-one in 
an analogous manner to the 5α-isomers described above (section 2.2.2). In this case 
it is the 3α-product which predominates [12], and two GC-MS peaks in 6.5:1 ratio 
were assigned as the 3α- and 3β-alcohols respectively in accordance with the 
literature precedent. 
 
2.2.4 5β-Estrane-3β,17α-diol 
5β-Estrane-3β,17α-diol was prepared from its 3α,17β-isomer by a Mitsunobu 
reaction with simultaneous stereochemical inversion at both C3 and C17. 
Diisopropyl azodicarboxylate (1.3 μL) was added to a suspension of 5β-estrane-
3α,17β-diol (1 mg) in a solution of 4-nitrobenzoic acid (1.1 mg) and 
triphenylphosphine (1.7 mg) in anhydrous ether (0.5 mL). The mixture was shaken 
until the steroid had completely dissolved (approx. 5 min), then was allowed to stand 
overnight at room temperature. The solution was diluted with ethyl acetate (5 mL), 
washed with sodium carbonate solution (1 M, 5 mL) and the organic fraction was 
dried by evaporation at 60 °C under a stream of nitrogen. The 4-nitrobenzoylated 
residue was reconstituted in methanol (1 mL) and sodium hydroxide solution (10 M; 
1 drop) was added. The solution was allowed to stand overnight at room 
temperature, then was diluted with hydrochloric acid (1 M, 5 mL) and extracted with 
ethyl acetate (5 mL). The organic fraction was dried by evaporation at 60 °C under a 
stream of nitrogen. The residue was purified by chromatography on a short silica 
column using ethyl acetate:dichloromethane (1:1 v/v) and the product was shown to 
be chromatographically resolved by GC from its three commercially available 
C3/C17 stereoisomers. 
 
2.2.5 1α-Methyl-5α-androstane-3β,17β-diol 
Mesterolone contains a 1α-methyl substituent oriented axially on the 5α-androstane 
steroid framework. As previously described [13], this group blocks the lower face of 
the 3-ketone such that hydride reduction affords mixtures of the 3α- and 3β-alcohols. 
Sodium borohydride reduction of the mesterolone gave a 1:1 mixture of the two 
alcohols on a small scale. Greater selectivity for the 3β-alcohol was afforded in this 
case by reduction with sodium in ethanol, giving the desired isomer in 70% yield. 
To a solution of mesterolone (30 mg) in ethanol (10 mL) was carefully added excess 
sodium metal. The solution was heated to reflux and the reaction was monitored by 
thin layer chromatography. On completion, the solution was cooled and ethanol (10 
mL) was slowly added followed by water (30 mL). The ethanol was evaporated under 
reduced pressure and the residual mixture was extracted with ethyl acetate (3 x 10 
mL). The extract was dried by evaporation under reduced pressure and the crude 
material was purified by chromatography on silica to give the pure product (21 mg, 
70%) as a white solid: Rf 0.49 (40% ethyl acetate in hexane); [α]20D +17 (c 1.40, 
CHCl3) (lit. [13] [α]29D +18 (c 1.0, CHCl3)); IR (thin film) 3420 (O-H), 2957, 2924, 2851 
(C-H) cm-1; 1H NMR (300 MHz, CDCl3) δ 3.76 (1H, tt, J 11.7, 4.8 Hz, H3), 3.56 (1H, t, 
J 8.4 Hz, H17), 2.08-1.89 (1H, m), 1.86-1.73 (2H, m), 1.71-1.37 (10H, m), 1.35-1.24 
(6H, m), 1.03-0.85 (4H, m), 0.95 (3H, s, CH3), 0.94 (3H, d, J 7.8Hz, CH3), 0.74 (3H, 
s, CH3); 13C NMR (75.45 MHz, CDCl3) δ 82.0, 67.0, 51.2, 48.9, 43.2, 38.9, 38.6, 
37.8, 37.6, 37.2, 36.8, 35.7, 31.5, 30.5, 28.8, 23.5, 20.2, 15.1, 14.4, 11.3; m/z (+EI) 
306 (M•+, 5%), 288 (4), 234 (6), 220 (6), 206 (6), 191 (41), 149 (15), 97 (20), 83 (76), 
49.0 (100); HRMS (+EI) calcd for C20H34O2 (M•+) 306.2559 found 306.2560. 
 
2.2.6 17α-Methyl-5β-androstane-3α,16α,17β-triol 
The title compound was synthesized from etiocholanolone by a modification of the 
method of Watabe et al. [14] and Leslie [15]. 
 
2.2.6.1 3α,17-Diacetoxy-5β-androst-16-ene [15] 
To a solution of etiocholanolone (1.5 g, 5.16 mmol) in isopropenyl acetate (25 mL) 
was added concentrated sulfuric acid (2 drops). The solution was heated in a 
distillation apparatus until the reaction volume had reduced by approximately half. 
The isopropenyl acetate was restored to its original volume and heating was 
continued. This concentration-dilution sequence was repeated for 5 h. The reaction 
mixture was diluted with diethyl ether (25 mL) and the organic layer was washed with 
saturated aqueous sodium hydrogen carbonate solution (3 x 10 mL) and brine (25 
mL). The organic layer was dried (MgSO4) and concentrated to give a brown solid. 
The crude material was purified by flash column chromatography using 10% ethyl 
acetate in hexane to give the title compound (1.28 g, 66%) as a white solid: Rf = 0.60 
(25% ethyl acetate in hexane); m.p. 89-90 °C (lit. [15] 90-91 °C); [α]20D +62.1 (c 1.0, 
CH3OH); IR (thin film) 2932, 2866 (C-H), 1734 (C=O) cm-1; 1H NMR (400 MHz, 
CDCl3) δ 5.44 (1H, m, H16), 4.71 (1H, m, H3), 2.15 (1H, m), 2.14 (3H, s, COCH3), 
2.02 (3H, s, COCH3), 1.93-0.98 (19H, m), 0.95 (3H, s, CH3) 0.86 (3H, s, CH3); 13C 
NMR (100 MHz, CDCl3) δ 170.9, 169.2, 159.9, 111.6, 74.4, 54.4, 45.1, 42.2, 41.3, 
35.2, 30.1, 34.2, 33.8, 32.5, 29.1, 27.1, 26.8, 25.8, 23.5, 21.7, 21.4, 20.5, 15.8; 
HRMS (+EI) calcd for C23H34O4 (M•+) 374.2457, found 374.2450. 
 
2.2.6.2 3α,16α-Diacetoxy-5β-androstan-17-one [14] 
To a solution of 3α,17-diacetoxy-5β-androst-16-ene (381.3 mg, 1.02 mmol) in 
dichloromethane (10 mL) was added meta-chloroperoxybenzoic acid (527.1 mg, 
3.05 mmol) in one portion. The reaction was stirred at room temperature for 1 h, at 
which point consumption of the starting material was indicated by TLC. The reaction 
mixture was washed with aqueous sodium hydroxide (1 M , 3 x 10 mL) and the 
organic layer was dried (MgSO4) and concentrated to give a white foam, which was 
used without further purification in the next step. The crude epoxide was dissolved in 
methanol (5 mL) and aqueous sulfuric acid (5 mL, 3 M) and stirred for 1 h at room 
temperature, after which TLC analysis showed consumption of the starting material. 
The reaction was diluted with ethyl acetate (20 mL) and extracted with aqueous 
sodium hydroxide (1 M, 3 x 10 mL). The organic layer was dried (MgSO4) and 
concentrated to give a white solid, which was used without further purification in the 
next step. The crude ketone was dissolved in acetic anhydride (5 mL) and pyridine (1 
mL) and the reaction was heated to 80 °C for 1.5 h, at which point consumption of 
the starting material was indicated by TLC. The crude reaction mixture was diluted 
with diethyl ether (20 mL) and washed with aqueous sodium hydroxide (1 M, 3 x 10 
mL), aqueous hydrochloric acid (3 x 10 mL, 1 M) and brine (10 mL). The organic 
layer was dried (MgSO4) and concentrated to give a white solid which was purified 
by flash column chromatography using 10% ethyl acetate in hexane to give the title 
compound (317.8 mg, 80% over 3 steps) as a white solid: [α]20D +75.3 (c 1.0, CHCl3); 
IR (thin film) 2937, 2866 (C-H), 1757, 1738 (C=O) cm-1; 1H NMR (400 MHz, CDCl3) δ 
5.36 (1H, dd, J 9.2, 0.8 Hz, H16), 4.69 (1H, m, H3), 2.15-1.00 (20H, m,), 2.08 (3H, s, 
COCH3), 1.99 (3H, s, COCH3), 0.931 (3H, s, CH3), 0.926 (3H, s, CH3); 13C NMR (100 
MHz, CDCl3) δ 214.1, 170.7, 170.4, 74.0, 72.6, 48.8, 47.8, 41.8, 40.7, 35.3, 35.0, 
34.8, 32.2, 31.6, 29.7, 26.7, 26.6, 25.0, 23.3, 21.5, 20.9, 19.8, 14.3; HRMS (+EI) 
calcd for C23H34O5 (M•+) 390.2406, found 390.2408. 
 
2.2.6.3 17α-Methyl-5β-androstane-3α,16α,17β-triol [14] 
A solution of 3α,16α-diacetoxy-5β-androstan-17-one (93.2 mg, 0.24 mmol) in diethyl 
ether (5 mL) was cooled to -78 °C and a solution of methylmagnesium bromide in 
ether (3 M, 1.99 mL, 5.97 mmol) was added. The reaction was maintained at -78 °C 
for 5 min before warming to 40 °C for 2 h. The crude reaction mixture was poured 
onto saturated ammonium chloride solution (25 mL) and diluted with ethyl acetate 
(20 mL). The organic layer was separated, dried (MgSO4) and concentrated to give a 
white solid. The crude product was purified by flash column chromatography using a 
gradient elution of 20%-40%-60%-80% ethyl acetate in hexane to afford (1) 17β-
methyl-5β-androstane-3α,16α,17α-triol as a white solid (13.6 mg, 18%): Rf 0.25 
(ethyl acetate); m.p. 238-240 °C (lit. [14] 240-241 °C); [α]20D -25.3 (c 1.0, CH3OH); IR 
(thin film) 3351 (O-H), 2982, 2862 (C-H), 1735 cm-1; 1H NMR (400 MHz, CD3OD) δ 
4.01 (1H, dd, J 2.8, 9.2 Hz, H16), 3.53 (1H, dddd, J 4.8, 4.8, 10.8, 10.8 Hz, H3), 
1.95-1.62 (7H, m), 1.53-1.15 (12H, m), 1.12 (3H, s, CH3), 1.01 (1H, m), 0.95 (3H, s, 
CH3), 0.70 (3H, s, CH3); 13C NMR (100 MHz, CD3OD) δ 81.2, 87.1, 72.4, 49.4, 48.0, 
43.6, 41.9, 37.2 (2C), 36.5, 35.8, 35.6, 31.7, 31.2, 28.2, 27.9, 24.0, 20.9, 20.3, 16.3; 
HRMS (EI+) calcd for C20H34O3 322.2508, found 322.2502; and (2) 17α-methyl-5β-
androstane-3α,16α,17β-triol as a white solid (31.1 mg, 40%): Rf 0.11 (ethyl acetate); 
m.p. 216-218 °C (lit. [14] 220-221 °C); [α]20D -2.6 (c 1.32, CH3OH); IR (thin film) 3339 
(O-H), 2921, 2857 (C-H) cm-1; 1H NMR (400 MHz, CD3OD) δ 4.17 (1H, dd, J 3.2, 
10.8 Hz, H16), 3.54 (1H, m, H3), 1.95-1.72 (4H, m), 1.64 (1H, m), 1.51-1.26 (14H, 
m), 1.15 (3H, s, CH3), 1.01 (1H, m), 0.96 (3H, s, CH3), 0.84 (3H, s, CH3); 13C NMR 
(100 MHz, CD3OD) δ 85.0, 80.7, 72.3, 49.6, 47.5, 43.6, 42.0, 37.7, 37.2, 36.4, 35.8, 
34.8, 33.3, 31.1, 28.3, 37.4, 23.9, 21.1, 18.2, 15.0; HRMS (+EI) calcd for C20H34O3 
322.2508, found 322.2508. The stereochemistry of the minor product (1) was 
confirmed by single crystal X-ray analysis [16]. 
 
2.2.7 19-Nor-5β,17α-pregnane-3α,16α,17β-triol and 19-nor-5β,17β-pregnane-
3α,16α,17α-triol 
The title compound was synthesized on a small scale from 19-noretiocholanolone by 
a route analogous to that described above (section 2.2.6), with the exception that the 
17β-ethyl substituent was introduced via the 17-ketone through a process of 
ethynylation with lithium acetylide ethylenediamine complex followed by 
hydrogenation [17]. GC-MS analysis revealed the existence of two peaks in 10:1 
ratio which were assigned as the 3α,16α,17β- and 3α,16α,17α-triols respectively 
based on the susceptibility of the latter to 16,17-isopropylidene acetal formation [18]. 
 
Syntheses of all four 19-nor-5,17α-pregnane-3,17β-diol C3/C5 isomers, both 19-nor-
5α,17α-pregnane-3β,16,17β-triol C16 isomers and both 19-nor-5α,17α-pregnane-
3β,17β,20-triol C20 isomers have been reported previously [19], as have syntheses 
of both 17α-methyl-5β-androstane-3,17β-diol C3 isomers and all eight 17α-
methylandrostane-3,16,17β-triol C3/C5/C16 isomers [18]. 
 
2.3 Animal Administrations 
All animal administration experiments were approved by the Queensland Department 
of Primary Industries and Fisheries Community Access Animal Ethics Committee. 
Urine samples were collected by spontaneous voiding and were immediately frozen 
and stored at -20 °C until required for analysis. 
 
2.3.1 Boldenone 
An oil solution of boldenone undecylenate (Boldebal-H®, Ilium, NSW, Australia; 1.1 
mL = 55 mg boldenone undecylenate) was administered by intramuscular injection to 
a female greyhound (9 years, 27 kg). Urine samples were collected pre-
administration and from 6 h-29 days post-administration. 
 
2.3.2 Danazol 
Danazol (Azol 100®, Alphapharm, NSW, Australia; 1 tablet = 100 mg danazol) was 
administered orally to a female greyhound (3.5 years, 23 kg). Urine samples were 
collected pre-administration and from 2 h-4 days post-administration. 
 
2.3.3 Ethylestrenol 
Ethylestrenol (Nandoral®, Intervet, VIC, Australia; 2 tablets = 1 mg ethylestrenol) 
was administered orally to a female greyhound (2.5 years, 26 kg). Urine samples 
were collected pre-administration and from 2 h-7 days post-administration. 
 
2.3.4 Mesterolone 
Mesterolone (Proviron®, Bayer Schering, NSW, Australia; 1 tablet = 25 mg 
mesterolone) was administered orally to a female greyhound (1.5 years, 29 kg). 
Urine samples were collected pre-administration and from 2 h-4 days post-
administration. 
 
2.3.5 Methandriol 
An oil solution of methandriol dipropionate (Anadiol Depot®, Ilium Veterinary 
Products, NSW, Australia; 1 mL = 75 mg methandriol dipropionate) was administered 
by intramuscular injection to a male greyhound (2 years, 35 kg). Urine samples were 
collected pre-administration and from 7 h-105 days post-administration. 
 
2.3.6 Nandrolone 
An oil solution of nandrolone laurate (Laurabolin®, Intervet/Schering-Plough Animal 
Health, VIC, Australia; 2 mL = 50 mg nandrolone laurate) was administered by 
intramuscular injection to a female greyhound (3 years, 27 kg). Urine samples were 
collected pre-administration and from 7 h-146 days post-administration. 
 
2.3.7 Norethandrolone 
Norethandrolone (Anaplex®, Jurox, NSW, Australia; 2.5 tablets = 12.5 mg 
norethandrolone) was administered orally to a female greyhound (4 years, 23 kg). 
Urine samples were collected prior to administration, then at 2, 4, 6, 8, 24, 32, 48, 56 
and 72 h post-administration. 
 
2.4 Sample Preparation2.4.1 Solid Phase Extraction 
Aliquots of urine (3 mL) were adjusted to pH 7 and centrifuged to sediment 
particulate matter. The supernatant fractions were loaded onto Waters Oasis WAX 
solid phase extraction cartridges (3 mL, 60 mg, 60 μL; P/N 186002492) which had 
previously been conditioned with methanol (1 mL) and water (3 mL). The cartridges 
were washed with sodium hydroxide solution (0.1 M, 3 mL), sodium phosphate buffer 
solution (0.05 M, pH 7.5, 3 mL) and water (3 mL), then were dried under vacuum to 
remove residual water. The cartridges were sequentially eluted with methanol:ethyl 
acetate (1:1 v/v, 3 mL; unconjugated fraction), methanol:ethyl acetate:formic acid 
(50:50:1 v/v/v, 3 mL; β-glucuronide conjugated fraction) and methanol:ethyl 
acetate:diethylamine (50:50:1 v/v/v, 3 mL; sulfate conjugated fraction) with several 
minutes drying under vacuum between the second and third elutions. All three 
eluates were dried by evaporation at 80 °C under nitrogen. 
 
2.4.2 Cleanup: Unconjugated Fraction 
Dried eluates were reconstituted in methanol (0.5 mL) and sodium hydroxide solution 
(2 M, 4 mL) and extracted with diisopropyl ether (4 mL). The extracts were dried by 
evaporation at 80 °C under nitrogen. 
 
2.4.3 Hydrolysis and Cleanup: β-Glucuronide Conjugated Fraction 
Dried eluates were reconstituted in sodium citrate buffer solution (0.1 M, pH 6, 0.5 
mL) and Escherichia coli β-glucuronidase solution (Sigma Type IX-A lyophilized 
powder, P/N G7396; 2 mg/mL, 50 μL) and incubated overnight at 37 °C. Sodium 
hydroxide solution (2 M, 4 mL) was added and the mixture was extracted with 
diisopropyl ether (4 mL). The extracts were dried by evaporation at 80 °C under 
nitrogen. 
 
2.4.4 Solvolysis and Cleanup: Sulfate Conjugated Fraction 
Dried eluates were reconstituted in anhydrous methanolic hydrogen chloride (1 M, 
0.5 mL) [20] and incubated for 15 min at 60 °C. Sodium hydroxide solution (2 M, 4 
mL) was added and the mixture was extracted with diisopropyl ether (4 mL). The 
extracts were dried by evaporation at 80 °C under nitrogen. 
 
2.4.5 Derivatisation: Oximination/tert-Butyldimethylsilylation 
Dried residues were reconstituted in a solution of hydroxylamine hydrochloride in 
pyridine (10% w/v, 50 μL) and incubated for 30 min at 100 °C. N-(tert-
butyldimethylsilyl)-N-methyltrifluoroacetamide (50 μL) was added and incubated for a 
further 60 min at 100 °C. The reaction was quenched by the addition of water (2 mL) 
and the mixture was extracted with hexane (2 mL). The extracts were dried by 
evaporation at 80 °C under nitrogen. 
 
2.4.6 Derivatisation: O-Methyloximination/tert-Butyldimethylsilylation 
Dried residues were reconstituted in a solution of methoxylamine hydrochloride in 
pyridine (2% w/v, 50 μL) and incubated for 30 min at 100 °C. A solution of tert-
butyldimethylsilyl trifluoromethanesulfonate in N-(tert-butyldimethylsilyl)-N-
methyltrifluoroacetamide (1% v/v; 50 μL) was added and incubated for a further 60 
min at 100 °C. The reaction was quenched by the addition of water (2 mL) and the 
mixture was extracted with hexane (2 mL). The extracts were dried by evaporation at 
80 °C under nitrogen. 
 
2.4.7 Derivatisation: O-Methyloximination/Trimethylsilylation 
Dried residues were reconstituted in a solution of methoxylamine hydrochloride in 
pyridine (2% w/v, 50 μL) and incubated for 30 min at 100 °C. The solutions were 
dried by evaporation at 80 °C, then were reconstituted in a solution of ammonium 
iodide and 1,4-dithioerythritol in N-methyl-N-trimethylsilyltrifluoroacetamide (0.2% 
and 0.4% w/v; 50 μL) and incubated for 60 min at 100 °C. The solutions were dried 
by evaporation at 80 °C under nitrogen. 
 
2.5 GC-MS Analyses 
Derivatized residues were reconstituted in dodecane (50 μL) for GC-MS analysis. 
Data were acquired using a Waters-Micromass Quattro triple quadrupole mass 
spectrometer interfaced to an Agilent 6890 gas chromatograph equipped with a SGE 
BPX-5 column (30 m x 0.25 mm I.D. x 0.25 µm film) and using helium as carrier gas. 
Sample injections (2 μL) were made in splitless mode with an injector temperature of 
200 °C. The column was held at 100 °C for 1 min, then was ramped at 10 °C/min to 
300 °C and held for a further 5 min. The column flow was maintained at 1 mL/min 
throughout the run and the purge valve was opened at 2 min to a split of 30:1. The 
detector was operated in electron ionization mode with a transfer line temperature of 
250 °C, source temperature of 200 °C and ionization energy of 70 eV. Full scan data 
were collected over the range m/z 50-700 with a scan time of 250 ms. 
 
3 Results & Discussion 
Post-administration urine samples were extracted as described above and subjected 
to three different derivatization procedures prior to GC-MS analysis. Putative 
metabolites were identified on the basis of their mass spectral characteristics and, 
where possible, confirmed against authentic reference standards. In the absence of 
any exclusively unconjugated 17α-alkyl metabolites, the formation of 17-epimerized 
artifacts from 17-sulfated 17α-alkyl-17β-hydroxy metabolites, as originally described 
by Edlund et al. [21], was not considered.3.1 Boldenone 
The canine metabolism of boldenone has been examined both in vitro and in vivo by 
Williams et al. [4,5]. Phase I pathways identified after incubation with canine liver 
microsomes included oxidation of the 17-hydroxyl group and hydroxylation at one or 
more other positions. In vivo, 41 urinary phase I metabolites arising from various 
permutations of single bond oxidation, double bond reduction and hydroxylation were 
observed after oral administration. Following intravenous administration, Brockwell et 
al. [6] reported the presence in urine of 5α-androstane-3β,17α-diol and 5α-
androstane-3β,17β-diol. 
In the present study, boldenone was administered intramuscularly as its long acting 
undecylenate ester. Eight metabolites were detected in urine [7]. Analytes confirmed 
by comparison with authentic reference standards were boldenone, androsta-1,4-
diene-3,17-dione, 5β-androst-1-ene-3,17-dione, epiandrosterone, 17β-hydroxy-5β-
androst-1-en-3-one and 5β-androst-1-ene-3α,17β-diol. In addition, two compounds 
showing mass spectra consistent with a dihydroxyandrostenone and an 
androstenetriol were detected but could not be definitively identified due to the 
unavailability of reference standards. 17-Epiboldenone, 5α-androst-1-ene-3,17-
dione, androsterone, etiocholanolone, 3-epietiocholanolone, 17β-hydroxy-5α-
androst-1-en-3-one, 5α-androst-1-ene-3α,17β-diol, 5α-androst-1-ene-3β,17β-diol 
and 5β-androst-1-ene-3β,17β-diol were not detected. Whole or partial phase II β-
glucuronylation was observed for all of the observed hydroxylated metabolites, while 
non-hydroxylated metabolites were unconjugated. No sulfate conjugated metabolites 
were detected. The detection time for some metabolites was in excess of 4 weeks 
following a single dose. 
The above pattern of phase I metabolites may be explained by a combination of 17-
oxidation, complete reduction of the Δ1,4-3-ketone with 3β,5α-stereochemistry, partial 
reduction of the Δ1,4-3-ketone with 3α,5β-stereochemistry and hydroxylation at an 
unidentified site (Fig. 1). 
 
3.2 Danazol 
The canine metabolism of danazol has not previously been reported, but ethisterone 
is a known major metabolite in humans, monkeys, rats [22] and horses [23] and was 
also detected in greyhound urine after oral danazol administration (Fig. 2). Extraction 
and derivatisation by O-methyloximination and tert-butyldimethylsilylation revealed 
ethisterone with a detection time of about 1 week. Most of the excreted ethisterone 
was β-glucuronide conjugated, the remainder being unconjugated. 
 
3.3 Ethylestrenol 
The canine metabolism of ethylestrenol has not previously been reported. In humans 
and monkeys it is metabolized by oxidation to norethandrolone followed by reduction 
of the Δ4-3-ketone and hydroxylation at C21 [24]; and in the rat [25] and horse 
[26,27] by a similar sequence of oxidation and reduction. 
The oral administration of ethylestrenol to a female greyhound allowed the detection 
of several potential urinary metabolites, but most were too weak to allow confident 
mass spectral interpretation. The strongest peak appeared to correspond to a 19-
norpregnanetriol with no additional hydroxylation on the D-ring or ethyl side chain 
(Fig. 3): the tris(tert-butyldimethylsilyl) derivative showed m/z 607 ([M-tBu•]+), 532 
([M-tBuMe2SiOH]•+), 477 ([M-tBu•-Me2SiO-C4H8]+), 269 ([M-tBu•-Me2SiO-
2tBuMe2SiOH]+), 199 (D-ring) and 186 (D-ring); the tris(trimethylsilyl) derivative 
showed m/z 538 (M•+), 509 ([M-Et•]+), 448 ([M-Me3SiOH]•+), 419 ([M-Et•-Me3SiOH]+), 
358 ([M-2Me3SiOH]•+), 268 ([M-3Me3SiOH]•+), 239 ([M-Et•-3Me3SiOH]+), 157 (D-ring) 
and 144 (D-ring) (Fig. 4). Clearly this compound differs from the identified 19-
norpregnanetriol metabolites of the related steroid norethandrolone (section 3.7). 
Ethylestrenol and norethandrolone were not detected, nor were any 19-nor-5,17α-
pregnane-3,17β-diols (4 isomers), 19-nor-5α,17α-pregnane-3β,16,17β-triols (2 
isomers) or 19-nor-5α,17α-pregnane-3β,17β,20-triols (2 isomers). The major 
metabolite was β-glucuronide conjugated and could be detected for 72 hours post-
administration. 
 
3.4 Mesterolone 
The canine metabolism of mesterolone has not previously been reported. In humans 
it is metabolized by reduction at C3 and oxidation at C17 [12] and in the horse by 
reduction at C3, hydroxylation at C16 and C18 and epimerization at C17 [28]. 
Following the oral administration of mesterolone to a greyhound, the presence of 7 
metabolites was revealed. Most could not be definitively identified due to a lack of 
reference standards, but the most intense metabolite peak was confirmed as 1α-
methyl-5α-androstane-3β,17β-diol (Fig. 5) using a synthesized standard (section 
2.2.5). The metabolites of unconfirmed structure gave mass spectra consistent with 
isomers of mesterolone (1 isomer), monohydroxylated mesterolone (3 isomers) and 
oxidized monohydroxylated mesterolone (2 isomers). Mesterolone, 1α-methyl-5α-
androstane-3α,17β-diol and 3α-hydroxy-1α-methyl-5α-androstan-17-one were not 
detected. Phase II metabolism took the form of β-glucuronylation with a minor 
degree of sulfation. No unconjugated metabolites were detected. The detection time 
for the major metabolite was about 48 hours. 
 
3.5 Methandriol 
The canine metabolism of methandriol has not previously been reported. In humans 
the major metabolite after oral administration is 17α-methyl-5β-androstane-3α,17β-
diol [12], while in the horse it is metabolized by reduction of the Δ5-unsaturation and 
hydroxylation at C16 and C19 [29,30]. 
In this work, the long acting methandriol dipropionate was administered by 
intramuscular injection. 3 urinary phase I metabolites were detected: methandriol, 
17α-methyl-5α-androstane-3β,17β-diol and 17α-methyl-5β-androstane-3α,16α,17β-
triol [8]. The triol, identified using synthesized reference standards and previously 
described GC-MS data [18], was the major metabolite and was detectable for 90 
days post-administration. It was subsequently synthesized on a larger scale and fully 
characterized (section 2.2.6). No 17α-methyltestosterone or other isomeric 17α-
methyl-5-androstane-3,17β-diols (3 isomers) or 17α-methyl-5-androstane-3,16,17β-
triols (7 isomers) were observed. All metabolites were β-glucuronide conjugated. The 
saturated metabolites are the same as are observed in the greyhound for following 
17α-methyltestosterone administration [9] suggesting the latter may be a metabolic 
intermediate (Fig. 6), although it was not observed in this case. 
 
3.6 Nandrolone 
Brockwell et al. [6] have previously reported the detection of nandrolone, estr-4-ene-
3,17-dione, 19-norepiandrosterone, 19-noretiocholanolone and some 
uncharacterized reduced and hydroxylated metabolites in urine following the 
intravenous administration of nandrolone to a greyhound. 
In the present study, an oil solution of the long acting nandrolone laurate was 
administered by intramuscular injection. A total of 6 metabolites was observed: 
nandrolone, 19-norepiandrosterone, 19-noretiocholanolone, 5α-estrane-3β,17α-diol, 
5α-estrane-3β,17β-diol and 5β-estrane-3α,17β-diol [8]. Estr-4-ene-3,17-dione, 17-
epinandrolone and 5β-estrane-3β,17β-diol were not detected, nor was there any 
evidence of the presence of other estrane-3,17α-diols (3 isomers). 5α-Estrane-
3β,17β-diol and 5β-estrane-3α,17β-diol were the major metabolites and were 
detectable for over 140 days. All metabolites were predominantly β-glucuronide 
conjugated. The above pattern may be explained by a combination of Δ4-3-ketone 
reduction with 3α,5β- or 3β,5α-stereochemistry, oxidation of the 17β-hydroxyl and 
reduction of the resulting 17-ketone with 17α-stereochemistry (Fig. 7). 
 
3.7 Norethandrolone 
The canine metabolism of norethandrolone has not previously been reported. In 
humans it is metabolized primarily by reduction of the Δ4-3-ketone and hydroxylation 
at C21 [24]; in marmoset monkeys by reduction and hydroxylation of the B-ring [24]; 
in cows by reduction [31] and in the horse by reduction, hydroxylation at C16 and 
C20 and full oxidation at C21 [19,32,33]. 
Following the oral administration of norethandrolone to a greyhound, five phase I 
urinary metabolites were detected. Of these two were identified by comparison with 
synthesized reference standards as 19-nor-5α,17α-pregnane-3β,17β-diol and (20R)-
19-nor-5α,17α-pregnane-3β,17β,20-triol and a third was tentatively identified as 19-
nor-5β,17α-pregnane-3α,16α,17β-triol using a partially characterised synthesised 
reference material (section 2.2.7). The diol metabolite was detectable for 24 h and 
the triols for 56 h post-administration. No other isomeric 19-nor-5,17α-pregnane-
3,17β-diols (3 isomers) were observed, nor were 19-nor-5α,17α-pregnane-
3β,16α,17β-triol, 19-nor-5α,17α-pregnane-3β,16β,17β-triol or (20S)-19-nor-5α,17α-
pregnane-3β,17β,20-triol. The remaining uncharacterized metabolites showed mass 
spectra consistent with a 19-norpregnane-3,17,20-triol and a 19-norpregnanetriol 
hydroxylated at C3, C17 and an additional site not on the D-ring or ethyl side chain. 
The 19-nor-5β,17α-pregnane-3α,16α,17β-triol and 19-norpregnane-3,17,20-triol 
metabolites displayed a mixture of β-glucuronide and sulfate conjugation, while the 
remaining metabolites were all present as β-glucuronides exclusively. This 
metabolism (Fig. 8) is analogous in some respects to that observed for methandriol 
and 17α-methyltestosterone (Fig. 7) but, interestingly, seems different to that 
observed for ethylestrenol (section 3.3), which acts as a norethandrolone prodrug in 
other species. 
 
3.8 Doping control 
Based on the above research together with previously published material [9], a 
screening method has been developed to monitor a wide range of AASs in urine 
from racing greyhounds. Samples are hydrolyzed with β-glucuronidase, then are 
purified using a simple reversed phase solid phase extraction. Extracted steroids are 
converted to their O-methyloxime and/or tert-butyldimethylsilyl derivatives (section 
2.4.6) and are analyzed by GC-MS in multiple reaction monitoring mode. The 
monitored transitions for the analytes described in this article appear in Table 1. 
 
4 Conclusions 
The GC-MS methodology developed here provides sub-ng/mL sensitivity for most 
analytes and, combined with LC-MS coverage for stanozolol [10], has successfully 
been used to control the use of AASs in racing greyhounds for over 4 years. During 
that time, numerous positive detections have been declared for boldenone, 
methandriol, nandrolone and stanozolol and/or their metabolites. 
 
Executive Summary 
Boldenone undecylenate was metabolized by hydrolysis followed by oxidation of the 
17β-hydroxyl, whole or partial reduction of the Δ1,4-3-ketone with 3α,5β- or 3β,5α-
stereochemistry and hydroxylation at an unidentified site. 
Danazol was converted in large part to ethisterone. 
The major metabolite of ethylestrenol was not fully characterized, but appears to be 
a 19-norpregnanetriol. 
Mesterolone was metabolized by reduction of the 3-ketone with 3β-stereochemistry, 
hydroxylation at an unidentified site or sites and hydroxyl oxidation. 
Methandriol dipropionate was metabolized by hydrolysis and apparent conversion to 
17α-methyltestosterone followed by reduction of the resulting Δ4-3-ketone with either 
3α,5β- or 3β,5α-stereochemistry and 16α-hydroxylation. 
Nandrolone laurate was metabolized by hydrolysis followed by oxidation and 
epimerization of the 17β-hydroxyl and reduction of the Δ4-3-ketone with 3α,5β- or 
3β,5α-stereochemistry. 
Norethandrolone was metabolized by reduction of the Δ4-3-ketone with either 3α,5β- 
or 3β,5α-stereochemistry and 16α-hydroxylation. 
Phase II β-glucuronylation of sterol metabolites is significant. 
 
 
 
Future perspective 
Future work will concentrate on expanding coverage for synthetic AASs and 
developing effective methods for controlling the use of endogenous AASs such as 
testosterone and its precursors. In the longer term, the identification of indirect 
markers for AAS administration or the use of longitudinal data to establish 
biochemical parameters for individual athletes show interesting potential for canine 
AAS control. 
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Table 1: MRM transitions used for AAS doping control. 
Analyte Marker for Precursor Transition 
(m/z) 
Retention 
time (min)d 
Androsta-1,4-diene-3,17-dione Boldenone M•+ 342→311 8.44e 
5β-Androst-1-ene-3α,17β-diol Boldenone [M-tBu•]+ 461→253 9.34 
5β-Androst-1-ene-3,17-dione Boldenone M•+ 344→313 8.08 
Boldenone Boldenone M•+ 429→398 10.20 
5α-Estrane-3β,17α-diol Nandrolone [M-tBu•]+ 449→241 9.82 
5α-Estrane-3β,17β-diol Nandrolone [M-tBu•]+ 449→241 10.59 
5β-Estrane-3α,17β-diol Nandrolone [M-tBu•]+ 449→241 10.14 
Ethisterone Danazol [M-Me•]+ 440→209 11.14e 
17β-Hydroxy-5β-androst-1-en-3-one Boldenone M•+ 431→374 9.82 
Methandriol Methandriol [M-tBu•]+ 475→343 12.83 
1α-Methyl-5α-androstane-3β,17β-diol Mesterolone [M-tBu•]+ 477→269 11.81 
17α-Methyl-5α-androstane-3β,17β-diol Methandriol, 
17α-Methyltestosterone 
[M-tBu•]+ 477→269 12.97 
17α-Methyl-5β-androstane-3α,16α,17β-triol Methandriol, 
17α-Methyltestosterone 
[C12H27Si2O2]+ a 259→147 16.50 
Nandrolone Nandrolone M•+ 417→360 9.73 
19-Norepiandrosterone Nandrolone [M-tBu•]+ 362→286 8.75 
19-Noretiocholanolone Nandrolone [M-tBu•]+ 362→286 8.54 
19-Nor-5α,17α-pregnane-3β,17β-diol Norethandrolone C15/C16/C17 b 199→73 13.45 
19-Nor-5β,17α-pregnane-3α,16α,17β-triol Norethandrolone [M-tBu•]+ c 493→269 17.10 
Unidentified 19-norpregnanetriol Ethylestrenol [C11H23SiO]+ b 199→73 17.00 
a C15, C16, C17 and substituents with loss of tBu•. 
b D-ring fragment equivalent to those described by Middleditch et al. [34] for 17-trimethylsilyloxysteroids. 
c M in this case is a bis(tert-butyldimethylsilyl) derivative. The free OH is presumably at C17. 
d Temperature program: 100 °C for 1 min, 40 °C/min to 300 °C, 300 °C for 12 min. All other conditions are as in 
section 2.5. 
e The O-methyloxime E- and Z-isomers are partly resolved. 
Figure 1: Identified phase I metabolites of boldenone undecylenate. 
 
 
Figure 2: The major phase I metabolite of danazol. 
 
Figure 3: The major phase I metabolite of ethylestrenol. 
 
 
Figure 4: Mass spectra for the (a) tert-butyldimethylsilylated and (b) trimethylsilylated 
derivatives of the major ethylestrenol metabolite. 
(a) 
 
(b) 
 
Figure 5: The major phase I metabolite of mesterolone. 
 
 
Figure 6: The phase I metabolism of methandriol dipropionate. 
 
 
Figure 7: The phase I metabolism of nandrolone laurate. 
 
 
Figure 8: The identified phase I metabolites of norethandrolone. 
 
